IPM Take
CRPS-1 is the kind of condition health systems often fail quietly. The pain is severe, the disability can be life-changing, and patients can spend years being misunderstood, delayed or undertreated. A pivotal Phase 3 trial of neridronate matters because CRPS-1 has no FDA-approved medicine. But this is not the moment to declare success. It is the moment to ask whether rare pain can finally be treated as a serious access and evidence problem, not as an afterthought.
Executive Summary
Ambros Therapeutics announced the first patient dosed in its pivotal CRPS-RISE Phase 3 trial of intravenous neridronate for complex regional pain syndrome type 1, CRPS-1. The randomized, triple-blind, placebo-controlled study will evaluate efficacy, safety and tolerability of neridronate versus placebo in adults with CRPS-1. Ambros states that CRPS-1 is a severe, debilitating rare disease with an estimated 65,000 new cases annually in the United States. Neridronate has previously received FDA Breakthrough Therapy, Fast Track and Orphan Drug designations for CRPS-1.
Why it matters
- Patients / advocates: CRPS patients often fight to be believed before they can even fight for treatment. A pivotal trial gives the field a clearer evidence route.
- Clinicians: Better evidence could help standardise care in a condition where diagnosis, referral and treatment can be inconsistent.
- Regulators / payers: If positive, this could force a serious access debate around rare pain, disability and long-term functional outcomes.
Pain can be invisible. CRPS is not gentle about that invisibility.
For many patients, complex regional pain syndrome begins after injury or trauma, then becomes something larger than the original event. Pain, swelling, colour changes, temperature changes, movement limitation and disability can take over the limb and the person’s life.
The first patient dosed in CRPS-RISE is therefore more than a trial milestone. It is a signal that rare pain is moving into a more formal evidence pathway.
Neridronate is being tested against placebo in a pivotal Phase 3 trial. The study is designed to support a potential FDA regulatory submission if successful. That is important because CRPS-1 currently has no FDA-approved medicine, leaving patients dependent on fragmented approaches, variable specialist access and often incomplete relief.
The implementation question is not only whether neridronate reduces pain. It is whether treatment changes function, mobility, sleep, work, mental health and dependence on crisis care. Rare pain access cannot be judged by pain scores alone.
For IPM, this article should be political. CRPS-1 exposes how health systems respond to pain they cannot easily measure. A rigorous Phase 3 trial is a step toward evidence, but the bigger test is whether evidence becomes recognition, referral and access.
